AnaCardio

All Events Fund articles Fund PR Portfolio articles Portfolio PR

AnaCardio receives patent grant in Europe for AC01

2025.03.132025.04.30 / Stockholm, Sweden and Lugano, Switzerland, March 13, 2025 - AnaCardio, a clinical-stage biopharmaceutical company developing novel contractile agents to treat patients with heart failure and Helsinn ...

AnaCardio reports first patient dosed in the phase 2a study evaluating AC01 in patients with heart failure and reduced ejection fraction (HFrEF)

2025.02.272025.04.30 / February 25, 2025, Stockholm, Sweden - AnaCardio, a clinical-stage biopharmaceutical company developing novel contractile agents to treat patients with heart failure today announced that the first pa ...

Applying the best of both science and business to treat heart failure

2025.01.312025.04.30 / AnaCardio is focused on bringing treatment for one of today’s largest unmet medical needs to market. According to CEO Patrik Strömberg, the Swedish biopharmaceutical company is leveraging strong scie ...

AnaCardio press release

2025.01.092025.04.30 / AnaCardio raises USD 19 million to advance first-in-class drug candidate AC01 for heart failure Reports positive results from phase 1b study of AC01 in patients with heart failure and reduce ...